Activation of the epidermal growth factor receptor (EGFR) pathway is an early event in head and neck carcinogenesis. As a result, there has been increased interest in targeting EGFR for chemoprevention. However, given the redundancy in molecular signaling of tumors, it is unlikely that inhibition of EGFR signaling alone would inhibit malignant progression of OSCC. In this regard, natural compounds or nutritional supplements with favorable safety profiles are particularly attractive for use as potential 'bio-adjuvants' for cancer prevention. To this end, our novel approach involves the use of the nutritional supplement, Vitamin D3 (or its active metabolite calcitriol) as a bio-adjuvant to enhance the chemopreventive efficacy of the EGFR inhibitor, Erlotinib. Two of the main downstream effects of the EGFR pathway involve activation of the MAPK- Erk and the PI3K-Akt pathways that are critically involved in cell survival, proliferation and angiogenesis. Calcitriol induces cleavage o MEK in a caspase-dependent manner and also decreases phosphorylation of Erk and Akt, that is necessary for their activation. It is therefore our hypothesis that targeting these interacting signaling pathways with calcitriol (or vitamin D) in combination with Erlotinib will be more effective in preventing oral cancer. The focus of the present work is to conduct a comprehensive preclinical investigation into the chemopreventive potential of this mechanistically-driven against oral cancer. Using carcinogen and PDX models, the proposed research plan will evaluate the chemopreventive efficacy (Aim 1 and 2) and dissect the molecular mechanisms (Aim 3) involved in the response of oral cancers to this combination regimen. Positive results would pave the way for use of vitamin D3 in combination with Erlotinib for the prevention of oral cancer.

Public Health Relevance

Oral squamous cell carcinomas (OSCC) are loco-regionally aggressive tumors that result in debilitating functional and esthetic sequelae in patients. The high rate of recurrence and the formation of second primary tumors have been attributed to a number of factors including field cancerization - the multifocal development of the disease in the mucosa following carcinogen exposure. This unique disease biology makes OSCC an ideal target for prevention and identification of safe and effective preventive strategies would have a major impact on quality of life and survival of these patients. The focus of the present work is to conduct comprehensive investigation of a novel mechanistically-driven chemopreventive strategy against oral cancer. Positive results from our studies would provide the rationale for clinical evaluation of our approach in the secondary or tertiary prevention setting.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
3R01DE024595-05S1
Application #
10215646
Study Section
Chemo/Dietary Prevention Study Section (CDP)
Program Officer
Wang, Chiayeng
Project Start
2016-07-16
Project End
2021-03-31
Budget Start
2020-07-16
Budget End
2021-03-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Vincent-Chong, V K; DeJong, H; Rich, L J et al. (2018) Impact of Age on Disease Progression and Microenvironment in Oral Cancer. J Dent Res 97:1268-1276
Rich, Laurie J; Miller, Austin; Singh, Anurag K et al. (2018) Photoacoustic Imaging as an Early Biomarker of Radio Therapeutic Efficacy in Head and Neck Cancer. Theranostics 8:2064-2078